
AJCC staging remains the foundation of melanoma care, yet a meaningful share of deaths arise in patients staged as lower risk. Dr. Singh examines where staging falls short and where molecular risk tools add clarity.

AJCC staging remains the foundation of melanoma care, yet a meaningful share of deaths arise in patients staged as lower risk. Dr. Singh examines where staging falls short and where molecular risk tools add clarity.

Not all gene expression profile assays carry the same evidentiary weight. Dr. Singh reviews validation data, survival outcomes, and how NCCN's 5% threshold shapes his choice of test.

A high-risk molecular result can change management in thin and node-negative melanoma. Dr. Singh explains how GEP findings shape sentinel node biopsy, imaging, and surveillance decisions.

Gaurav Singh, MD, explores how gene expression profiling may improve melanoma risk stratification, surveillance, and individualized care.